References
1. Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e737S-e801S.
2. Monagle P, Cuello CA, Augustine C, et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv.2018;2(22):3292-3316.
3. Kahn SR, Solymoss S, Lamping DL, Abenhaim L. Long-term outcomes after deep vein thrombosis: postphlebitic syndrome and quality of life.J Gen Intern Med. 2000;15(6):425-429.
4. van Korlaar IM, Vossen CY, Rosendaal FR, et al. The impact of venous thrombosis on quality of life. Thrombosis research.2004;114(1):11-18.
5. van Korlaar I, Vossen C, Rosendaal F, Cameron L, Bovill E, Kaptein A. Quality of life in venous disease. Thrombosis and haemostasis.2003;90(1):27-35.
6. Lubberts B, Paulino Pereira NR, Kabrhel C, Kuter DJ, DiGiovanni CW. What is the effect of venous thromboembolism and related complications on patient reported health-related quality of life? A meta-analysis.Thrombosis and haemostasis. 2016;116(3):417-431.
7. Kahn SR, Ducruet T, Lamping DL, et al. Prospective evaluation of health-related quality of life in patients with deep venous thrombosis.Arch Intern Med. 2005;165(10):1173-1178.
8. Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics. 2009;124(4):1001-1008.
9. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol. 2020.
10. Spiezia L, Boscolo A, Poletto F, et al. COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. Thrombosis and haemostasis. 2020.
11. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020.
12. Vedantham S, Goldhaber SZ, Julian JA, et al. Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. The New England journal of medicine. 2017;377(23):2240-2252.
13. Enden T, Haig Y, Kløw NE, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet (London, England). 2012;379(9810):31-38.
14. Notten P, Ten Cate-Hoek AJ, Arnoldussen C, et al. Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial. The Lancet Haematology. 2020;7(1):e40-e49.
15. Dandoy CE, Kukreja KU, Gruppo RA, Patel MN, Tarango C. Outcomes in children with deep vein thrombosis managed with percutaneous endovascular thrombolysis. Pediatric radiology.2015;45(5):719-726.
16. Gaballah M, Shi J, Kukreja K, et al. Endovascular Thrombolysis in the Management of Iliofemoral Thrombosis in Children: A Multi-Institutional Experience. Journal of vascular and interventional radiology : JVIR. 2016;27(4):524-530.
17. Goldenberg NA, Branchford B, Wang M, Ray C, Jr., Durham JD, Manco-Johnson MJ. Percutaneous mechanical and pharmacomechanical thrombolysis for occlusive deep vein thrombosis of the proximal limb in adolescent subjects: findings from an institution-based prospective inception cohort study of pediatric venous thromboembolism.Journal of vascular and interventional radiology : JVIR.2011;22(2):121-132.
18. Goldenberg NA, Durham JD, Knapp-Clevenger R, Manco-Johnson MJ. A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children.Blood. 2007;110(1):45-53.
19. Mitchell LG, Goldenberg NA, Male C, Kenet G, Monagle P, Nowak-Göttl U. Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children.Journal of thrombosis and haemostasis : JTH. 2011;9(9):1856-1858.
20. Kahn SR, Comerota AJ, Cushman M, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association.Circulation. 2014;130(18):1636-1661.
21. Avila ML, Pullenayegum E, Williams S, Yue N, Krol P, Brandão LR. Postthrombotic syndrome and other outcomes of lower extremity deep vein thrombosis in children. Blood. 2016;128(14):1862-1869.
22. Loja MN, Brunson A, Li CS, et al. Racial disparities in outcomes of endovascular procedures for peripheral arterial disease: an evaluation of California hospitals, 2005-2009. Ann Vasc Surg.2015;29(5):950-959.
23. Lemaire A, Cook C, Tackett S, Mendes DM, Shortell CK. The impact of race and insurance type on the outcome of endovascular abdominal aortic aneurysm (AAA) repair. Journal of vascular surgery.2008;47(6):1172-1180.
24. White RH, Dager WE, Zhou H, Murin S. Racial and gender differences in the incidence of recurrent venous thromboembolism. Thrombosis and haemostasis. 2006;96(3):267-273.
25. Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.The Lancet Haematology. 2019.
26. Tarango C, Manco-Johnson MJ. Pediatric Thrombolysis: A Practical Approach. Front Pediatr. 2017;5:260.
27. Fleming GA, Khan M, Janssen D, Doyle T. Angiojet rheolytic thrombectomy in infants following cardiac surgery. Catheter Cardiovasc Interv. 2010;76(2):233-240.
28. Dwarka D, Schwartz SA, Smyth SH, O’Brien MJ. Bradyarrhythmias during use of the AngioJet system. Journal of vascular and interventional radiology : JVIR. 2006;17(10):1693-1695.
29. Sarper N, Zengin E, Aylan S, Gelen, Babaoglu K. PB2437 THROMBOLYTIC THERAPY IN PEDIATRIC PATIENTS; OUTCOME AND COMPLICATIONS OF TISSUE PLASMINOGEN ACTIVATOR. HemaSphere. 2019;3(S1):1079-1080.
30. Manco-Johnson MJ, Grabowski EF, Hellgreen M, et al. Recommendations for tPA thrombolysis in children. On behalf of the Scientific Subcommittee on Perinatal and Pediatric Thrombosis of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thrombosis and haemostasis. 2002;88(1):157-158.
31. Ansah DA, Patel KN, Montegna L, Nicholson GT, Ehrlich AC, Petit CJ. Tissue Plasminogen Activator Use in Children: Bleeding Complications and Thrombus Resolution. The Journal of pediatrics.2016;171:67-72.e61-62.
32. Leaker M, Massicotte MP, Brooker LA, Andrew M. Thrombolytic therapy in pediatric patients: a comprehensive review of the literature.Thrombosis and haemostasis. 1996;76(2):132-134.
33. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood.1987;70(1):165-172.
34. Andrew M, Brooker L, Leaker M, Paes B, Weitz J. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration. Thrombosis and haemostasis. 1992;68(3):325-330.